- Home
- ARVN vs KOD Comparison
ARVN vs KOD Comparison
Compare ARVN & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARVN | KOD |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 806.0M | 795.5M |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ARVN | KOD |
|---|---|---|
| Price | $12.61 | $24.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 7 |
| Target Price | $17.80 | ★ $22.29 |
| AVG Volume (30 Days) | ★ 2.3M | 712.7K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $312,300,000.00 | N/A |
| Revenue This Year | $11.06 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 93.86 | N/A |
| 52 Week Low | $5.90 | $1.92 |
| 52 Week High | $24.77 | $26.21 |
Technical Indicators
Market Signals| Indicator | ARVN | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 57.85 | 60.93 |
| Support Level | $11.66 | $21.24 |
| Resistance Level | $13.56 | $26.21 |
| Average True Range (ATR) | 0.57 | 1.78 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 61.43 | 69.40 |
Price Performance
Historical ComparisonAbout ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.